Bristol-Myers Asked to Seek Special Coverage for Opdivo in U.K.

  • Opdivo not cost-effective for all lung-cancer patients: NICE
  • Company advised to seek payment from U.K. Cancer Drugs Fund

Bristol-Myers Squibb Co.’s Opdivo lung-cancer treatment isn’t cost-effective for all patients, and the company should seek to make it accessible to some through a special U.K. government program, the country’s health-cost regulator said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.